These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21453844)

  • 1. Guidelines for assessment of cardiovascular disease in life insurance.
    O'Rourke MF; Clubb J
    J Am Coll Cardiol; 2011 Apr; 57(14):1570-1; author reply 1571. PubMed ID: 21453844
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for high-risk cardiovascular disease: a challenge for the guidelines: comment on "systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check?".
    Smith SC
    Arch Intern Med; 2010 Jan; 170(1):40-2. PubMed ID: 20065197
    [No Abstract]   [Full Text] [Related]  

  • 3. A total cardiovascular risk estimate should not be used dichotomously.
    De Backer G
    J Hypertens; 2006 Sep; 24(9):1697-8. PubMed ID: 16915014
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: Cardio-vascular status and life insurance.
    Shah SJ
    Indian Heart J; 1973 Jul; 25(3):153-6. PubMed ID: 4773879
    [No Abstract]   [Full Text] [Related]  

  • 5. [Heart and blood circulation diagnostics. Deliberations from the viewpoint of life-insurance medicine].
    Raestrup O
    Lebensversicher Med; 1978 May; 30(3):50-60. PubMed ID: 25998
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular risk factors, BMI and mortality in a cohort of Swiss males (1976-2001) with high-sum-assured life insurance cover.
    Baldinger B; Schwarz C; Jaggy C
    J Insur Med; 2006; 38(1):44-53. PubMed ID: 16642642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reason for the cardiovascular test.
    Parman CC
    J Cardiovasc Manag; 2005; 16(2):5-6. PubMed ID: 15813206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The science of lipidology impacts underwriting and improves mortality.
    Gleeson R
    J Insur Med; 2009; 41(3):197-200. PubMed ID: 20377099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for preparticipation screening and the assessment of cardiovascular disease in masters athletes.
    Hecht HS
    Circulation; 2001 Sep; 104(11):E58. PubMed ID: 11551892
    [No Abstract]   [Full Text] [Related]  

  • 10. Natriuretic peptide testing--ready for insurance screening?
    MacKenzie R
    J Insur Med; 2007; 39(3):153-6. PubMed ID: 18251372
    [No Abstract]   [Full Text] [Related]  

  • 11. Hope for the future: early recognition of increased cardiovascular risk in children and how to deal with it.
    Masi S; Charakida M; Wang G; O'Neill F; Taddei S; Deanfield J
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S61-4. PubMed ID: 19675441
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic information and life insurance: a 'real' risk?
    Joly Y; Knoppers BM; Godard B
    Eur J Hum Genet; 2003 Aug; 11(8):561-4. PubMed ID: 12891375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional tests for cardiovascular diseases, their usefulness in life insurance medicine.
    BIORCK G
    Acta Med Scand Suppl; 1953; 277():76-87. PubMed ID: 13065025
    [No Abstract]   [Full Text] [Related]  

  • 14. Heart association issues new guidelines on cardiovascular disease prevention in women.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Feb; 15(4):1-2, 6-7. PubMed ID: 15000094
    [No Abstract]   [Full Text] [Related]  

  • 15. Return-to-play decisions in athletes with cardiac conditions.
    Lawless CE
    Phys Sportsmed; 2009 Apr; 37(1):80-91. PubMed ID: 20048491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of guidelines of the management of cardiovascular risk factors in diabetic patients with macrovascular disease.
    Kollias A; Xilomenos A; Ikonomopoulou K; Tolis A
    Int Angiol; 2010 Feb; 29(1):87-8. PubMed ID: 20224540
    [No Abstract]   [Full Text] [Related]  

  • 17. [The risk of suffering a cardiovascular disease in the making of decisions. From evidence to the clinic].
    Villar Alvarez F; Maiques Galán A; Franch Taix M; Banegas Banegas JR; Vilaseca Canals J
    Med Clin (Barc); 1999; 112 Suppl 1():67-73. PubMed ID: 10618802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic testing in insurance underwriting: a blessing or a curse? An examination of the tension between economics and equity in using genetic testing in risk classification.
    Anderson MC
    Creighton Law Rev; 1992 Jun; 25(4):1499-535. PubMed ID: 11654461
    [No Abstract]   [Full Text] [Related]  

  • 19. Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension.
    Ruilope LM; Segura J
    Clin Ther; 2005 Oct; 27(10):1658-68. PubMed ID: 16330303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The latest from the IVD industry: ever-growing importance of laboratory diagnostics in treating cardiovascular disease.
    Clin Lab; 2005; 51(1-2):55-8. PubMed ID: 15719706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.